Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea · Delayed Price · Currency is KRW 38,900
-2,050 (-5.01%)
At close: Jun 10, 2026
Next Biomedical Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Next Biomedical stock has a consensus rating of "Strong Buy" and an average price target of ₩97,667. The average 1-year stock price forecast is 151.07% higher than the current stock price, while the lowest is ₩83,000 (+113.37%) and the highest is ₩120,000 (+208.48%).
Price Target: ₩97,667 (+151.07%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Next Biomedical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Financial Forecast
Revenue This Year
23.20B
from 16.48B
Increased by 40.80%
Revenue Next Year
36.30B
from 23.20B
Increased by 56.47%
EPS This Year
-455.00
from -38.00
EPS Next Year
801.00
from -455.00
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 23.2B | ||
| Avg | 23.2B | ||
| Low | 23.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 40.8% | ||
| Avg | 40.8% | ||
| Low | 40.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -455.00 | ||
| Avg | -455.00 | ||
| Low | -455.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |